Title: Relationship between GSTP1 and XPG genetic polymorphisms and survival of platinum-based chemotherapy in advanced non-small cell lung cancer patients
Abstract: Background and purpose:The present study aimed to investigate the relationship between glutathione S-transferase P1(GSTP1) A105G and xeroderma pigmentatosum group G(XPG) C46T genetic polymorphisms and the effects and survival of platinum-based chemotherapy in advanced non-small cell lung cancer(NSCLC) patients.Methods:The DNA of 85 patients with NSCLC was extracted from peripheral venous blood before chemotherapy.GSTP1 and XPG genotypes were detected by DNA sequencing methods.The clinical response was evaluated after two cycles of chemotherapy.Time to progression(TTP) and overall survival(OS) were evaluated,and the relationship between GSTP1 and XPG genotypes and chemotherapeutic efficiency as well as survival were analyzed.Results:Patients with GSTP1 A/G+G/G genotype showed a chemotherapeutic efficiency of 43.59% compared to patients with A/A genotype of 19.57%(χ2=5.738,P0.05),and patients with XPG C/C genotype showed a chemotherapeutic efficiency of 42.86% compared to patients with C/T+T/T genotype of 18.60%(χ2=5.886,P0.05);Patients with GSTP1 A/G+G/G and XPG C/C genotype showed the highest chemotherapeutic efficiency of 44.74%(P0.05).The median TTP was 6.5 months for the 81 patients followed-up;8.0 months for GSTP1 A/G+G/G genotype,and 6.0 months for GSTP1 A/A genotype(P0.01),and patients with XPG C/C genotype had a longer median TTP(7.5 months) than patients with XPG C/T+T/T genotype(6.0 months,P0.01).Patients with GSTP1 A/G+G/G and XPG C/C genotype had the longest median TTP of 8.0 months(P0.01).The median OS for 78 patients followed-up was 9.0 months;11.0 months for GSTP1 A/G+G/G genotype,and 9.0 months for A/A genotype(χ2=14.522,P0.01),and patients with XPG C/C genotype had a longer median OS(10.5 months) than patients with XPG C/T+T/T genotype(9.0 months,P0.01).Patients with GSTP1 A/G+G/G and XPG C/C genotype had the longest median OS of 11.0 months(P0.01).Conclusion:The GSTP1 A105G and XPG C46T polymorphisms might be potential prognostic factors of clinical response and survival in patients with advanced NSCLC receiving platinum-based chemotherapy.
Publication Year: 2012
Publication Date: 2012-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 3
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot